Takeda is in talks to sell Shire’s experimental inflammatory bowel disease pipeline in an effort to meet European regulators approval for the acquisition.
Half of drug discovery will eventually be outsourced as the service area goes the way of contract toxicology, according to the CEO of Charles River Laboratories (CRL).
Contract research organisations (CROs) are slashing clinical trial
times by an average of 30 per cent and the outsourcing trend is
showing no signs of slowing, as the pharma industry continues to
face rising pressure to reduce time-to-market...
Outsourcing-Pharma focus on: Phase IIIB-IV research
The US Food & Drug Administration's (FDA) drive to clear the
mounting backlog of post-marketing (Phase IV) drug trials signals
good news for the clinical research organisations (CROs) who are
poised to benefit.
Outsourcing-Pharma: Focus on Phase IIIB-IV research
The spate of recent high-profile drug recalls, culminating in the
dramatic high profile withdrawal of Vioxx in 2004, has fuelled a
trend of consolidation within the Phase IIIB-IV clinical trials
outsourcing sector that looks set to...
As pharma companies continue to search for new areas of business to
outsource, third party logistics (3PL) is an area tipped for
dramatic growth over the next four years, particularly in Europe
where the practice is still in its infancy,...
